Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic.

Download full-text PDF

Source
http://dx.doi.org/10.15586/aei.v51i3.786DOI Listing

Publication Analysis

Top Keywords

transient self-resolving
12
treated dupilumab
8
asthma atopic
8
atopic dermatitis
8
dupilumab
5
hyperthyroidism 15-year-old
4
15-year-old adolescent
4
adolescent treated
4
dupilumab severe
4
severe allergic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!